Abstract: The present invention relates to anti-HER2 single domain antibodies, polypeptides comprising thereof and their use for treating cancer.

Abstract: The present invention relates to antigen binding formats for use in therapeutic treatments or diagnostic assays. The present invention relates to an antigen-binding format consisting of: —a first fusion protein wherein the CH1 constant domain of an antibody is fused i) by its N-terminal end to the C-terminal end of a variable domain of an antibody and ii) by its C-terminal end to the N-terminal end of a variable domain of an antibody and, —a second fusion protein wherein the CL constant domain of an antibody is fused by its N-terminal end to the C-terminal end of a variable domain of an antibody.

Abstract: The present invention relates to anti-Natural Killer Group 2 member D (NKG2D) single domain antibodies and uses thereof in particular in the therapeutic field.

Abstract: The present disclosure provides isolated nanobodies based on camelid VHH domains that specifically bind to mesothelin with high affinity. Also disclosed are conjugate constructs comprising the isolated nanobodies derivatized to allow conjugation to or that are conjugated to accessory moieties, such as biologically active moieties (e.g., a cytotoxin, a non-cytotoxic drug, a radioactive agent, a protein, or an enzyme) or detectable markers (e.g., a fluorescent label or biotin). Nucleic acid molecules encoding the nanobodies and conjugate constructs, expression vectors, host cells and methods for expressing the nanobodies and conjugate constructs are also provided. Pharmaceutical compositions comprising the nanobodies and conjugate-constructs as described herein are also provided. The present invention is also directed to methods for detecting mesothelin, as well as methods for diagnosis, treating, preventing and ameliorating mesothelin-associated diseases and conditions (e.g.

Abstract: The present invention relates to antigen binding formats for use in therapeutic treatments or diagnostic assays. The present invention relates to an antigen-binding format consisting of:—a first fusion protein wherein the CH1 constant domain of an antibody is fused i) by its N-terminal end to the C-terminal end of a variable domain of an antibody and ii) by its C-terminal end to the N-terminal end of a variable domain of an antibody and,—a second fusion protein wherein the CL constant domain of an antibody is fused by its N-terminal end to the C-terminal end of a variable domain of an antibody.

Abstract: The present invention relates to antigen binding formats for use in therapeutic treatments or diagnostic assays. The present invention relates to an antigen-binding format consisting of: —a first fusion protein wherein the CH1 constant domain of an antibody is fused i) by its N-terminal end to the C-terminal end of a variable domain of an antibody and ii) by its C-terminal end to the N-terminal end of a variable domain of an antibody and, —a second fusion protein wherein the CL constant domain of an antibody is fused by its N-terminal end to the C-terminal end of a variable domain of an antibody.

Abstract: The present invention relates to anti-HER2 single domain antibodies, polypeptides comprising thereof and their use for treating cancer.

Abstract: The present invention relates to antigen binding formats for use in therapeutic treatments or diagnostic assays. The present invention relates to an antigen-binding format consisting of: a first fusion protein wherein the CH1 constant domain of an antibody is fused i) by its N-terminal end to the C-terminal end of a variable domain of an antibody and ii) by its C-terminal end to the N-terminal end of a variable domain of an antibody and, a second fusion protein wherein the CL constant domain of an antibody is fused by its N-terminal end to the C-terminal end of a variable domain of an antibody.